ImmunoPrecise Antibodies Ltd. Stock Toronto S.E.
Equities
IPA
CA45257F2008
Pharmaceuticals
Sales 2024 * | 24.59M 17.94M | Sales 2025 * | 29.82M 21.75M | Capitalization | 43.89M 32.02M |
---|---|---|---|---|---|
Net income 2024 * | -12M -8.75M | Net income 2025 * | -9M -6.57M | EV / Sales 2024 * | 1.78 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.47 x |
P/E ratio 2024 * |
-3.48
x | P/E ratio 2025 * |
-4.71
x | Employees | 102 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.41% |
Latest transcript on ImmunoPrecise Antibodies Ltd.
Managers | Title | Age | Since |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 18-02-20 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 23-09-28 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 23-09-04 |
Jennifer Bath
CEO | Chief Executive Officer | - | 18-02-20 |
1st Jan change | Capi. | |
---|---|---|
-2.86% | 87.37B | |
+4.08% | 41.01B | |
-20.76% | 28.08B | |
+53.30% | 24.72B | |
-3.91% | 17.47B | |
-42.09% | 11.69B | |
-18.33% | 11.6B | |
-12.10% | 11.56B | |
+1.65% | 8.44B |